14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ANRO vs SGMO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin).
Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY).
Technical & Structure Timing Caution: ANRO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.6); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs SGMO. Trailing 12-month operating profitability (ANRO 0.0% vs SGMO -175.5%) and valuation multiples (ANRO N/M vs SGMO 0.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ANRO vs SGMO Key Questions & Quantitative Answers
As of Nov 16, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Sangamo Therapeutics, Inc. (SGMO) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ANRO carries a Unified Composite Score of 29.3/100 (SELL) at $27.77 (N/M Forward P/E, 0.0% operating margin), whereas SGMO carries 52.0/100 (HOLD) at $0.18 (0.4x Forward P/E, -175.5% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. ANRO 29.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY). Technical & Structure Timing Caution: ANRO trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.6); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SGMO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $40M for SGMO. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.
SGMO screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus SGMO (-2891.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.95β · 89% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.